ICYMI: FDA commissioner calls for more onshoring of clinical trials
FDA Commissioner Robert Califf took to the stage twice in the last 12 hours in San Francisco, lining up his priorities and digging in on vaccine misinformation, accelerated approval reforms, and a renewed interest in onshoring more clinical trials where companies may be trying to save money, particularly in oncology.
Taking the stage early Tuesday at the JP Morgan conference, Califf told attendees that the recently passed omnibus spending law is “really important” for the agency to more quickly help sponsors verify or disprove the benefits of accelerated approvals.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.